Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb study of pirepemat for reducing falls in Parkinson's disease
2019-002627-16Phase 2Completed
- Sponsor
- IRLAB
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Pirepemat in Parkinson's disease (PD) (3 arms), sponsored by IRLAB. Primary endpoint: Change in falls frequency. Started Dec 2021; status: completed.
02
Drugs
Pirepemat
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2019-002627-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002627-16.